Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 70 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Moderate and Severe Active Rheumatoid Arthritis Clear all
Completed Phase 3 Interventional Results available

A Moderate to Severe Rheumatoid Arthritis Study

NCT01721044
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Baricitinib, cDMARD
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
32
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 6, 2026, 2:01 PM EDT
Recruiting Phase 1 Interventional

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

NCT07041099
View directory record Official record
Conditions
Sjögren, Sjogren Disease, Sjogren's Syndrome
Interventions
CLN-978
Drug
Lead sponsor
Cullinan Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Orlando, Florida • Brooklyn, New York • Memphis, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 6, 2026, 2:01 PM EDT
Completed Phase 3 Interventional

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

NCT05814627
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Upadacitinib, Adalimumab, Upadacitinib Matching Placebo, Adalimumab Matching Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
85
States / cities
Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 6, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

NCT02760407
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w, Placebo q2w
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
64
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 6, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis

NCT02638259
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GP2015
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Peoria, Arizona • Phoenix, Arizona • El Cajon, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 6, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)

NCT00891020
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra], Nonbiologic DMARDs of investigator's choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
227
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 201 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 6, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis

NCT02744755
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab - GP2017, Adalimumab - US licensed Humira
Biological
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Mesa, Arizona • Peoria, Arizona • Covina, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 6, 2026, 2:01 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

NCT05516758
View directory record Official record
Conditions
Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases
Interventions
Peresolimab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
54
States / cities
Birmingham, Alabama • Gilbert, Arizona • Glendale, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 6, 2026, 2:01 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of SPY072 in Rheumatic Disease

NCT07148414
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases, Rheumatic Joint Disease, PsA (Psoriatic Arthritis), AxSpA, Rheumatologic Disease
Interventions
SPY002-072, Placebo
Drug
Lead sponsor
Spyre Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Avondale, Arizona • Tucson, Arizona • Chula Vista, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 6, 2026, 2:01 PM EDT
Completed Phase 2 Interventional Results available

Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants

NCT02065700
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
15
States / cities
Gilbert, Arizona • Mesa, Arizona • Hemet, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 6, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis

NCT03120949
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab 64 mg SC q4w, Olokizumab 64 mg SC q2w, Concomitant treatment
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
2,106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
71
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 6, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 6, 2026, 2:01 PM EDT
Completed Phase 4 Interventional Results available

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

NCT01185288
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab, Methotrexate
Biological · Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
46
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 6, 2026, 2:01 PM EDT
Completed Phase 2 Interventional

An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

NCT05848258
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY3871801, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Huntington Beach, California • Doral, Florida • Ocoee, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 6, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs

NCT02706847
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
103
States / cities
Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 6, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

NCT01194414
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab SC, tocilizumab IV, placebo to tocilizumab SC, placebo to tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
54
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Oct 6, 2026, 2:01 PM EDT
Completed Phase 2 Interventional Results available

Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

NCT02969044
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, PF-06651600
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Northridge, California • St Louis, Missouri • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 6, 2026, 2:01 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

NCT00531817
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Placebo, Permitted DMARDs
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
156
States / cities
Birmingham, Alabama • Montgomery, Alabama • Lake Havasu City, Arizona + 135 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Oct 6, 2026, 2:01 PM EDT
Terminated Phase 2 Interventional Results available

A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy

NCT03001219
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Anti-TNF-alpha, Methotrexate, Placebo, RO7123520
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
32
States / cities
Anniston, Alabama • Glendale, Arizona • Mesa, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 6, 2026, 2:01 PM EDT
Active, not recruiting Phase 3 Interventional

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

NCT06245408
View directory record Official record
Conditions
Sjögren's Syndrome (SS)
Interventions
Dazodalibep, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
41
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 6, 2026, 2:01 PM EDT
Terminated Phase 1 Interventional

A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis

NCT06087406
View directory record Official record
Conditions
Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
Interventions
Imvotamab, Placebo
Drug
Lead sponsor
IGM Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Flagstaff, Arizona • Glendale, Arizona • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 6, 2026, 2:01 PM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)

NCT01888874
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GLPG0634, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
28
States / cities
Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 6, 2026, 2:01 PM EDT
Completed Phase 2 Interventional Results available

Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

NCT02015520
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Clazakizumab, Placebo (Matching with Clazakizumab)
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
21
States / cities
Huntsville, Alabama • Hot Springs, Arkansas • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 6, 2026, 2:01 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

NCT01682512
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
BI 695500, Rituxan®, MabThera®
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
54
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Oct 6, 2026, 2:01 PM EDT